n-3 fatty acid supplementation and leukocyte telomere length in patients with chronic kidney disease
Files
(Published version)
Date
2016
Authors
Barden, A.
O Callaghan, N.
Burke, V.
Mas, E.
Beilin, L.J.
Fenech, M.
Irish, A.B.
Watts, G.F.
Puddey, I.B.
Huang, R.C.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Nutrients, 2016; 8(3):1-11
Statement of Responsibility
Anne Barden, Nathan O'Callaghan, Valerie Burke, Emile Mas, Lawrence J. Beilin, Michael Fenech, Ashley B. Irish, Gerald F. Watts, Ian B. Puddey, Rae-Chi Huang and Trevor A. Mori
Conference Name
Abstract
DNA telomere shortening associates with the age-related increase cardiovascular disease (CVD) risk. Reducing oxidative stress, could modify telomere erosion during cell replication, and CVD risk in patients with chronic kidney disease (CKD). The effect of n-3 fatty acids and coenzyme Q10 (CoQ) on telomere length was studied in a double-blind placebo-controlled trial in CKD. Eighty-five CKD patients were randomized to: n-3 fatty acids (4 g); CoQ (200 mg); both supplements; or control (4 g olive oil), daily for 8 weeks. Telomere length was measured in neutrophils and peripheral blood mononuclear cells (PBMC) at baseline and 8 weeks, with and without correction for cell counts. Main and interactive effects of n-3 fatty acids and CoQ on telomere length were assessed adjusting for baseline values. F2-isoprostanes were measured as markers of oxidative stress. There was no effect of n-3 fatty acids or CoQ on neutrophil or PBMC telomere length. However, telomere length corrected for neutrophil count was increased after n-3 fatty acids (p = 0.015). Post-intervention plasma F2-isoprostanes were negative predictors of post-intervention telomere length corrected for neutrophil count (p = 0.025).The effect of n-3 fatty acids to increased telomere length corrected for neutrophil count may relate to reduced oxidative stress and increased clearance of neutrophils with shorter telomeres from the circulation. This may be a novel mechanism of modifying CVD risk in CKD patients.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).